Skip to content

Patient retention challenges and the need for more active follow-up

CROI: High rate of virologic failure on once-daily combination of 3TC, tenofovir and nevirapine

CROI: Rate of CD4 decline is a poor guide to the risk of AIDS, say investigators

CROI: Recent OIs or AIDS strongest predictors of development of resistance in South African first-line failures

CROI: Effects of transmitted drug resistance on viral load are drug class specific

CROI: Ugandan study confirms low CD4 count, low body weight, TB and anaemia major risk factors for death after starting ART

CROI: Lower CD4 count on HIV treatment predicts higher risk of cancers, liver, kidney, cardiovascular disease

CROI: Efavirenz-based ART more effective than nevirapine-based ART as first-line therapy in Southern Africa

Once-daily nevirapine has more side-effects than twice-daily dose, needs more study